Shares of Gujarat Themis Biosyn Ltd rose more than 6% after the company secured shareholder approval for a Qualified Institutional Placement (QIP) and reported strong results for the first quarter of FY27.

The pharmaceutical company posted operational income of ₹43.79 crore and a net profit of ₹11.07 crore for the quarter, with the bottom line rising 22% year-on-year.

A QIP is a capital-raising tool that allows listed Indian companies to issue shares to qualified institutional buyers without a lengthy public offering process, provided shareholders approve the enabling resolution. Shareholder approval is enabling in nature — it permits the board to launch a QIP within the timeline allowed under market regulations, but the company has not yet announced the size, pricing, or timing of any actual issue.

Gujarat Themis Biosyn is engaged in the manufacture of active pharmaceutical ingredients (APIs) and bulk drugs, operating in the pharmaceuticals sector. The company fits into India's API industry, which has been a policy focus area for the government in recent years through production-linked incentive schemes aimed at reducing reliance on imports of key starting materials. The newly approved QIP route, if exercised, would give the company access to institutional capital that API makers have typically used to fund capacity expansion and working-capital needs.

Investors will be watching for further company disclosures on whether and when the QIP is launched, the funds to be raised, and the intended use of proceeds, alongside whether the earnings momentum seen in the first quarter carries into subsequent quarters.

Source: CNBC-TV18